Axon insider plans sale of 10,000 common shares

Axon Enterprise, Inc. insider trading plan: An affiliate of Patrick W. Smith has filed to sell 10,000 shares of Axon common stock through UBS Financial Services on or about August 7, 2026, on Nasdaq, with an aggregate market value of $5,263,200.00.

Rhea-AI Filing Summary

Axon Enterprise, Inc. insider trading plan: An affiliate of Patrick W. Smith has filed to sell 10,000 shares of Axon common stock through UBS Financial Services on or about August 7, 2026, on Nasdaq, with an aggregate market value of $5,263,200.00. The filing also lists prior sales by Smith over the past three months totaling 40,000 shares for combined proceeds exceeding $21.4 million.

Key Figures

Planned shares to be sold: 10,000 shares Aggregate market value of planned sale: $5,263,200.00 Shares outstanding: 81,237,415 shares +3 more

6 metrics

Planned shares to be sold 10,000 shares Common stock to be sold through UBS Financial Services on or about August 7, 2026

Aggregate market value of planned sale $5,263,200.00 Value assigned to 10,000 Axon common shares to be sold on Nasdaq

Shares outstanding 81,237,415 shares Axon common shares referenced as outstanding in the filing

Sale on June 4, 2026 20,000 shares for $10,000,000.00 Common stock sale by Patrick W. Smith during past three months

Sale on June 29, 2026 10,000 shares for $5,000,018.00 Common stock sale by Patrick W. Smith during past three months

Sale on July 7, 2026 10,000 shares for $6,437,894.85 Common stock sale by Patrick W. Smith during past three months

Key Terms

Form 144, Option Exercise, aggregate market value, Nasdaq

4 terms

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Option Exercise financial

"Common | 11/15/2021 | Option Exercise | Issuer"

aggregate market value financial

"Common | UBS Financial Services, Inc. ... | 10000 | 5263200.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Nasdaq market

"81237415 | 08/07/2026 | Nasdaq"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Axon (AXON) insider Patrick W. Smith plan to sell under this Form 144?

Patrick W. Smith, via UBS Financial Services, plans to sell 10,000 shares of Axon common stock on or about August 7, 2026 on Nasdaq, with an indicated aggregate market value of $5,263,200.00.

How many AXON shares has Patrick W. Smith sold in the last three months?

Over the past three months, Patrick W. Smith has sold a total of 40,000 shares of Axon common stock in three transactions: 20,000 shares on June 4, 2026, and 10,000 shares each on June 29 and July 7, 2026.

What were the dollar amounts of Patrick W. Smith’s recent AXON share sales?

The disclosed sales totaled $10,000,000.00 on June 4, 2026, $5,000,018.00 on June 29, 2026, and $6,437,894.85 on July 7, 2026, reflecting proceeds from selling Axon common stock.

What aggregate market value is assigned to the planned 10,000 AXON shares sale?

The planned sale of 10,000 Axon common shares is shown with an aggregate market value of $5,263,200.00, based on the pricing information provided alongside the Nasdaq listing details.

How many Axon (AXON) shares are referenced as outstanding in this Form 144?

The Form 144 references 81,237,415 Axon common shares as outstanding, providing context for the relative size of the planned 10,000-share sale compared with the company’s total shares outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:12 PM Accepted by SEC EDGAR 08/07/2026 - 04:12 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001167028
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AXON ENTERPRISE, INC.
SEC File Number	001-16391
Address of Issuer	17800 N. 85TH ST. SCOTTSDALE ARIZONA 85255
Phone	480-991-0797
Name of Person for Whose Account the Securities are To Be Sold	SMITH PATRICK W
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	10000	5263200.00	81237415	08/07/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/15/2021	Option Exercise	Issuer			10000	11/15/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick W. Smith 17800 N. 85th ST. Scottsdale AZ 85255	Common	06/04/2026	20000	10000000.00
Patrick W. Smith 17800 N. 85th ST. Scottsdale AZ 85255	Common	06/29/2026	10000	5000018.00
Patrick W. Smith 17800 N. 85th ST Scottsdale AZ 85255	Common	07/07/2026	10000	6437894.85

144: Remarks and Signature

Remarks
Date of Notice	08/07/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Patrick W. Smith
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)